Program
Topotecan
Also written as “topotecan”, “topotecan hydrochloride” and “Topotecan/Docetaxel combination”.
Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 15 companies.
Drug pageTopotecan: every studyMany companies study it; this page follows only the 33 they lead. All 251 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 180 open or running | phase 3since Aug 14, 2002 | Nov 2, 1999 | none ahead |
| Bristol-Myers Squibbits history only | 20 open or running | phase 2since Sep 10, 2005 | Sep 10, 2005 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since Dec 10, 2015 | Dec 10, 2015 | none ahead |
| Advenchen Laboratoriesits history only | 11 open or running | phase 3since Aug 28, 2015 | Aug 28, 2015 | none ahead |
| Ascenta Therapeuticsits history only | 10 open or running | phase 2since Nov 7, 2006 | Nov 7, 2006 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 2since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| BioNTechits history only | 11 open or running | phase 2since Jun 3, 2024 | Jun 3, 2024 | Jun 2027phase 2 · NCT06449209 |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 2since Mar 6, 2012 | Mar 6, 2012 | none ahead |
| Gilead Sciencesits history only | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 3since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jun 17, 2022 | Jun 17, 2022 | none ahead |
| Pfizerits history only | 10 open or running | phase 2since Oct 9, 2018 | Oct 9, 2018 | none ahead |
| Sichuan Biokin Pharmaceuticalits history only | 11 open or running | phase 3since Jul 8, 2024 | Jul 8, 2024 | Dec 2026phase 3 · NCT06500026 |
| SynerGene Therapeuticsits history only | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
Also a collaborator on its studies: Eisai, Baili-Bio (Chengdu) Pharmaceutical and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Nov 1, 1999.
- Jun 16, 2008Phase 2 study in Small Cell Lung CarcinomaGlaxoSmithKline · NCT00698516 · 50 enrolled · United States
- Aug 11, 2008Phase 1 study in Solid TumoursGlaxoSmithKline · NCT00732420 · 68 enrolled · United States, Netherlands
- Mar 6, 2012Chong Kun Dang Pharmaceutical’s first study: phase 2 study in Carcinoma, Ovarian EpithelialNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT01630018 · 141 enrolled · Korea, Republic of
- Sep 11, 2012Hoffmann-La Roche’s first study: phase 3 study in Ovarian NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT01684878 · 208 enrolled · Austria, Belgium, Denmark and more
- Dec 18, 2014SynerGene Therapeutics’ first study: phase 1 study in NeoplasmsNew to SynerGene TherapeuticsSynerGene Therapeutics · NCT02354547 · 18 enrolled · United States
- Aug 28, 2015Advenchen Laboratories’ first study: phase 3 study in Endometrial NeoplasmsNew to Advenchen LaboratoriesAdvenchen Laboratories · NCT02584478 · 294 enrolled · United States, China, Italy and more
- Dec 10, 2015AbbVie’s first study: phase 3 study in Carcinoma, Ovarian EpithelialNew to AbbVieAbbVie · NCT02631876 · 366 enrolled · United States, Belgium, Bosnia and Herzegovina and more
- Oct 9, 2018Pfizer’s first study: phase 2 study in Sarcoma, EwingNew to PfizerPfizer · NCT03709680 · 128 enrolled · United States, Brazil, Canada and more
- Jun 17, 2022Novartis’s first study: phase 1 study in NeuroblastomaNew to NovartisNovartis · NCT05429502 · 12 enrolled · United States, Germany, Italy and more
- Nov 4, 2022Phase 2 study in Ovarian NeoplasmsBristol-Myers Squibb · NCT05613088 · 106 enrolled · United States, Australia, Belgium and more
- Jun 3, 2024BioNTech’s first study: phase 2 study in Small Cell Lung CarcinomaNew to BioNTechBioNTech · NCT06449209 · 110 enrolled · United States, Australia, South Korea and more
- Jul 8, 2024Sichuan Biokin Pharmaceutical’s first study: phase 3 study in Small Cell Lung CarcinomaNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT06500026 · 722 enrolled · China
- Jan 24, 2025Gilead Sciences’ first study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)New to Gilead SciencesGilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
- Oct 28, 2026Phase 2 study terminatedStudy stoppedNCT05613088 · “Business objectives have changed.”
Ahead
- Dec 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT06500026
- Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06449209
- Oct 2029Primary completion: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)Gilead Sciences · NCT06801834
TargetBeta
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule
Other programs on TOP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| irinotecan sucrosofaterule | CSPC Pharmaceutical Group | phase 3 | 20 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Gilead Sciences | Oct 2029 | 695 |
| NCT06500026Small Cell Lung Carcinoma · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 722 |
| NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more | 2 | Active, not recruiting | BioNTech | Jun 2027 | 110 |
| NCT05613088Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Jun 17, 2024 | 106 |
| NCT05429502Neuroblastoma · United States, Germany, Italy and more | 1 | Terminated | Novartis | Feb 26, 2025 | 12 |
| NCT03709680Sarcoma, Ewing · United States, Brazil, Canada and more | 2 | Completed | Pfizer | Aug 26, 2024 | 128 |
| NCT02631876Carcinoma, Ovarian Epithelial · United States, Belgium, Bosnia and Herzegovina and more | 3 | Completed | AbbVie | Jan 2019 | 366 |
| NCT02584478Endometrial Neoplasms · United States, China, Italy and more | 3 | Active, not recruiting | Advenchen Laboratories | Oct 2024 | 294 |
| NCT02354547Neoplasms · United States | 1 | Suspended | SynerGene Therapeutics | Dec 2027 | 18 |
| NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more | 3 | Completed | Hoffmann-La Roche | Jan 30, 2015 | 208 |
| NCT01630018Carcinoma, Ovarian Epithelial · Korea, Republic of | 2 | Completed | Chong Kun Dang Pharmaceutical | Jun 2014 | 141 |
| NCT00732420Solid Tumours · United States, Netherlands | 1 | Completed | GlaxoSmithKline | Jun 12, 2013 | 68 |
| NCT00698516Small Cell Lung Carcinoma · United States | 2 | Completed | GlaxoSmithKline | May 2010 | 50 |
| NCT00483860Neoplasms · United States, Korea, Republic of, Netherlands | 1 | Completed | GlaxoSmithKline | Feb 6, 2012 | 59 |
| NCT00437073Breast Neoplasms · United States, Austria, Belgium and more | 2 | Terminated | GlaxoSmithKline | Jan 2009 | 22 |
| NCT00397293Small Cell Lung Carcinoma · United States, Russian Federation, Ukraine | 2 | Completed | Ascenta Therapeutics | Dec 2008 | 36 |
| NCT00390806Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more | 3 | Completed | GlaxoSmithKline | Jul 2012 | 472 |
| NCT00361803Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Aug 9, 2007 | 15 |
| NCT00320359Small Cell Lung Carcinoma · Austria, Germany | 3 | Completed | GlaxoSmithKline | Feb 2007 | 700 |
| NCT00276276Small Cell Lung Carcinoma · Bulgaria, Hungary, Netherlands and more | 3 | Completed | GlaxoSmithKline | 141 | |
| NCT00267488Endometrial Neoplasms · United States, Canada, Hungary | 2 | Completed | GlaxoSmithKline | Dec 2007 | 70 |
| NCT00259935Small Cell Lung Carcinoma · United States, Netherlands | 1 | Completed | GlaxoSmithKline | Jul 5, 2007 | 107 |
| NCT00179712Ovarian Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | 60 | |
| NCT00158886Carcinoma, Renal Cell · United States | 1 | Terminated | GlaxoSmithKline | Aug 11, 2006 | 26 |
| NCT00065182Carcinoma, Non-Small-Cell Lung · United States, Canada, Poland | 2 | Completed | GlaxoSmithKline | Aug 30, 2007 | 399 |
| NCT00061308Ovarian Neoplasms · United States, Canada | 2 | Completed | GlaxoSmithKline | Sep 2004 | 75 |
| NCT00049998Carcinoma, Non-Small-Cell Lung · Australia, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 2004 | 760 |
| NCT00046111Small Cell Lung Carcinoma · United States, Canada | 1 | Completed | GlaxoSmithKline | Apr 2004 | 1 |
| NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Jan 2004 | 760 |
| NCT00043862Small Cell Lung Carcinoma · United States | 2 | Completed | GlaxoSmithKline | Nov 2005 | 60 |
| NCT00014690Fallopian Tube Neoplasms · United States | 2 | Completed | AstraZeneca | ||
| NCT00002395HIV Infections · United States | 2 | Completed | GlaxoSmithKline | 54 | |
| NCT00003827Leukemia · United States | 2 | UNKNOWN | Johnson & Johnson | 25 |
How it is read
Names in the registry
- “Topotecan”, 15 entries
- “topotecan”, 11 entries
- “topotecan hydrochloride”, 2 entries
- “Topotecan/Docetaxel combination”, 1 entry
- “Topotecan (Chemotherapy)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 11 studies
- Ovarian Neoplasms, 4 studies
- Neoplasms, 3 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.